Barcelona has solidified its position as a global life sciences hub, serving as a premier destination for pharmaceutical leaders and high-growth biotechnology startups.
The city is renowned for its healthcare innovation, fueled by a dense network of over 1,750 companies and 91 world-class research centers.
As a leader in clinical research, Barcelona ranks 5th in Europe for clinical trials, offering an unparalleled environment for drug development and advanced therapies, including CAR-T and gene editing.
The ecosystem is anchored by top-tier university hospitals like Hospital Clínic and Vall d'Hebron, which bridge the gap between academic research and clinical application.
In the medical device and medtech sectors, the region excels in 3D printing, robotic surgery and diagnostic imaging, supported by cutting-edge scientific facilities like the ALBA Synchrotron.
Barcelona is also at the forefront of the digital health revolution, with a booming startup scene focused on artificial intelligence, telemedicine and personalized medicine.
Global pharmaceutical giants such as AstraZeneca, Sanofi and Novartis have established strategic R&D hubs in the city, drawn by a highly skilled workforce and competitive operating costs.
The BioRegion of Catalonia continues to attract significant venture capital investment, particularly in oncology and rare diseases.
With the upcoming development of the BioCluster of Innovation and Health, Barcelona is set to further expand its capacity for large-scale biomanufacturing and sustainable healthcare solutions. This collaborative ecosystem makes the city a vital gateway for international companies seeking to scale within the European market.
Barcelona is home to major tertiary hospitals including Hospital Clínic, Hospital de la Santa Creu i Sant Pau, Hospital del Mar and Vall d’Hebron University Hospital. In December 2024, these institutions joined the HUB Alzheimer Barcelona initiative to coordinate research on neurodegenerative diseases.
Barcelona hosts several globally ranked universities with strong biomedical programs, including University of Barcelona, Universitat Autònoma de Barcelona, Universitat Pompeu Fabra and Universitat Politècnica de Catalunya. Research giants include the Barcelona Biomedical Research Park (PRBB), housing six public research centers and ~1,400 staff, and the Institute for Bioengineering of Catalonia (IBEC), designated a Severo Ochoa Center of Excellence.
In 2023, institutes and research groups at the Barcelona Science Park (PCB) mobilized ~$77 million in funding (including ~$63 million from public sources and ~$14 million from private capital) a 39.8% increase over 2022. Notable contributions included IRB Barcelona (~$39.9 million), IBEC (~$20.4 million), CNAG ($11.54 million) and IBMB-CSIC (~$5.71 million).
Healthcare startups and scaleups in Catalonia raised nearly ~$385 million in 2024, the second-highest annual total on record. Barcelona is also positioned to benefit from a proposed ~$55 million to $110 million early-stage life sciences investment fund backed by public and private partners, including the European Investment Bank.
Barcelona’s ecosystem includes more than 1,750 life sciences companies, of which about 550 are startups and scaleups, according to a 2023 report by CBRE. Foreign companies account for roughly 25% of sector turnover, reflecting the city’s growing role as a preferred location for international pharma and biotech operations.
Catalonia hosts about 50% of Spain’s pharmaceutical industry, including 79 production plants, with most activity concentrated in Barcelona. Local leaders including Almirall, Grifols, Esteve, Ferrer, Reig Jofré, Bioiberica, Salvat and Werfen are also headquartered in Barcelona. Subsidiaries and R&D operations in Barcelona include AstraZeneca, Merck, Amgen, Johnson & Johnson, Medtronic, Novartis, Pfizer, Roche and Sanofi. In April 2025, Sanofi announced a new innovation hub in the 22@ district, expected to create 300 jobs in AI, data science and biostatistics.
Barcelona also hosts headquarters or operations of 17 of the world’s top 20 pharma and medtech companies. The city has become a hub for medtech and digital health expansion. Qiagen is relocating its QIAstat-Dx operations to a new site in the city by 2026, and Teladoc Health established its international headquarters in 2018 in the city. Barcelona also ranks as Europe’s #2 hub for digital health startups, with ~400 companies in 2023, 41.5% of which are developing AI-driven health applications.
Across Barcelona, Spain, around 2,700 active clinical trials are in progress. Catalonia ranked 5th in Europe and 8th globally for the number of clinical trials in 2024.
Barcelona, Spain
Catalonia’s life sciences and healthcare sector employed nearly 75,400 people in 2023, accounting for 7.3% of the region’s employed population, with 94% of these jobs concentrated in Barcelona. The city and surrounding province host more than 1,000 companies and institutions, generating over ~$28.08 billion (€24 billion) in turnover. Talent development is strong, with Catalonia producing 25,000 life sciences graduates each year, giving Barcelona one of the highest concentrations of PhDs in Europe.
Barcelona added new capacity in 2024 with the opening of VHIR’s 17,000 m² research building. Other projects under development include DeepLabs - BaSID (~75,000 m² planned health innovation district), the MIES-UB building at the Science Park (to host Fraunhofer and IBEC groups) and the Biopol-Granvia Master Plan, a government-approved framework for an Innovation and Health BioCluster in the Barcelona metro area. Within the Science Park itself, existing institutes accounted for ~13,000 m² of research space in 2023.
Claim Profile to Update Website
Claim Profile to Update Contact Information
Claim Your Profile to Add Related Links
Claim Your Profile to add downloadable documentation
https://pharmaville.com/wp-content/uploads/2026/02/Pharmaville-Barcelona-references.pdf
